Canaccord Genuity Downgrades Botanix Pharmaceuticals
Canaccord Genuity has downgraded Botanix Pharmaceuticals from a 'Buy' to a 'Hold' rating.
Stocks · News reference
Canaccord Genuity Adjusts Price Target on Regeneron Pharmaceuticals
Canaccord Genuity has revised its price target for Regeneron Pharmaceuticals, increasing it from $875 to $922.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
UBS Maintains Neutral on CF Industries Holdings, Raises Price Target to $134
UBS Adjusts Price Target on CF Industries Holdings to $134
UBS has revised its price target for CF Industries Holdings, Inc. from $123 to $134 while maintaining a Neutral rating.